
BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Nectar Life Care announces launch of new anti-diabetic formulations

17 February 2025 | News

Product range will be available across India starting mid-February



Ahmedabad-based Nectar Life Care, the generic division of Kashmik Formulation, has announced the launch of a new range of high-quality, cost-effective anti-diabetic formulations, with Dapagliflozin, under the brand name DAPNEC.

The range also includes SITANEC M 50/500 & 50/1000 – Metformin and Sitagliptin Tablets; METNEC-G1 & METNEC G2 – Metformin and Glimepiride Tablets; and METNEC 500mg - Metformin Tablets.

With the expiration of API patents, these medicines will now be available at affordable prices, enhancing accessibility while maintaining high efficacy.

Manufactured in a WHO-GMP-certified facility, the range is designed to meet international quality standards while ensuring affordability. The company reported Rs 6.4 crore in sales last year, and is anticipating to cross the Rs 15 crore mark this year with the introduction of its diabetes care portfolio.

India, often called the ‘Diabetes Capital of the World,’ faces a rising demand for effective diabetes management solutions. Type 2 diabetes, once prevalent among adults, is now increasingly affecting younger individuals due to sedentary lifestyles, poor dietary habits, and rising obesity rates. According to the Indian Council of Medical Research (ICMR), over 77 million people in India have diabetes, with a significant portion undiagnosed. Studies by the Indian Diabetes Risk Score (IDRS) indicate that more than 10% of urban Indian youth are at risk, underscoring the need for comprehensive and accessible healthcare solutions.

Nilesh Patel, Founder of Nectar Life Care, said, "The launch of our cost-effective Dapagliflozin and upcoming diabetic formulations is a step toward ensuring quality diabetes care reaches those who need it most, regardless of financial constraints. Looking ahead, we plan to expand our portfolio with a dedicated anti-obesity range to combat the growing health risks associated with rising obesity."